PinPoint Publications

PinPoint Testing, LLC

PinPoint Testing, LLC – Publications since 2010  
(* denotes PinPoint Testing, LLC authors)

Grim TW, Morales AJ, Gonek MM, Wiley JL, Thomas BF, Endres GW, Sim-Selley LJ, Negus SS, Lichtman AH.

Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays. J Pharmacol Exp Ther. 2016 Nov;359(2):329-339. Epub 2016 Aug 17.

Pfannkoch EA, Stuff JR, Whitecavage JA, Blevins JM, Seely KA*, Moran JH*.

A high throughput method for measuring polycyclic aromatic hydrocarbons in seafood using QuEChERS extraction and SBSE. Int J Anal Chem. 2015;359629.

Su MK, Seely KA*, Moran JH*, Hoffman RS.

Metabolism of classical cannabinoids and the synthetic cannabinoid JWH-018. Clin Pharmacol Ther. 2015; 97(6):562-524.

Stolarz AJ, Rusch NJ*.

Gender differences in cardiovascular drugs. Cardiovasc Drug Ther. 2015; 29(4):403-410.

Takematsu M, Hoffman RS, Nelson LS, Schechter JM, Moran JH*, Wiener SW.

A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid. Clin Toxicol (Phila). 2014; 52(9):973-975.

Patton AL*, Seely KA*, Pulla S, Rusch NJ*, Moran CL*, Fantegrossi WE, Knight LD, Marraffa JM, Kennedy PD, James LP, Endres GW*, Moran JH*.

Quantitative measurement of acetyl fentanyl and acetyl norfentanyl in human urine by LC-MS/MS. Anal Chem. 2014; 86(3):1760-1766.

Fantegrossi WE, Moran JH*, Radominska-Pandya A, Prather PL.

Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity? Life Sci. 2014; 97(1):45-54.

Seely KA*, Patton AL*, Moran CL*, Womack ML, Prather PL, Fantegrossi WE, Radominska-Pandya A, Endres GW*, Channell KB, Smith NH, McCain KR, James LP, Moran JH*.

Forensic investigation of K2, Spice, and “bath salt” commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int. 2013; 233(1-3):416-422.

Fantegrossi WE, McCain KR, Moran JH*, Hoffman RS.

Not simply synthetic tetrahydrocannabinol. J Pediatr. 2013; 163(6):1797-1798.

Chimalakonda KC, James LP, Radominska-Pandya A, Moran JH*.

Sulfaphenazole and α-naphthoflavone attenuate the metabolism of the synthetic cannabinoids JWH-018 and AM2201 found in K2/spice. Drug Metab Lett. 2013; 7(1):34-38.

Patton AL*, Chimalakonda KC, Moran CL*, McCain KR, Radominska-Pandya A, James LP, Kokes C, Moran JH*.

K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci. 2013; 58(6):1676-1680.

Nedosekin DA, Juratli MA, Sarimollaoglu M, Moore CL, Rusch NJ*, Smeltzer MS, Zharov VP, Galanzha EI.

Photoacoustic and photothermal detection of circulating tumor cells, bacteria and nanoparticles in cerebrospinal fluid in vivo and ex vivo. J Biophotonics. 2013; 6(6-7):523-533.

Rajasekaran M, Brents LK, Franks LN, Moran JH*, Prather PL.

Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol Appl Pharmacol. 2013; 269(2):100-108.

Jones DR, Moran JH*, Miller GP.

Warfarin and UDP-glucuronosyltransferases: writing a new chapter of metabolism. Drug Metab Rev. 2010; 42(1):55-61.

Endres GW, Worst TJ, Sprague JE. 

“Designer drugs: legislating for tomorrow through the use of class definitions and pharmacophore principles.”  In Chromatographic techniques in the forensic science analysis of designer drugs.  Teresa Kowalska, editor.  CRC Press, Taylor & Francis Group. In press.

Patton AL*, Seely KA*, Chimalakonda KC, Tran JP, Trass M, Miranda A, Fantegrossi WE, Kennedy PD, Dobrowolski P, Radominska-Pandya A, McCain KR, James LP, Endres GW*, Moran JH*.

Targeted metabolomic approach for assessing human synthetic cannabinoid exposure and pharmacology. Anal Chem. 2013; 85(19):9390-9399.

Seely KA*, Brents LK, Radominska-Pandya A, Endres GW*, Keyes GS, Moran JH*, Prather PL.

A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chem Res Toxicol. 2012; 49(8):825-827.

Stratton SL, Henrich CL, Matthews NI, Bogusiewicz A, Dawson AM, Horvath TD, Owen SN, Boysen G, Moran JH*, Mock DM.

Marginal biotin deficiency can be induced experimentally in humans using a cost-effective outpatient design. J Nutr. 2012; 142(1):22-26.

Bratton SM, Mosher CM, Khallouki F, Finel M, Court MH, Moran JH*, Radominska-Pandya A.

J Pharmacol Exp Ther. 2012; 340(1):46-55.

Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases. 

Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH*, Prather PL.

Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol. 2012; 83(7):952-961.

Hirenallur-S DK, Detweiler ND, Haworth ST, Leming JT, Gordon JB, Rusch NJ*.

Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets. Pulm Circ. 2012; 2(2):193-200.

Seely KA*, Lapoint J, Moran JH*, Fattore L.

Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 39(2):234-243.

Chimalakonda KC, Seely KA*, Bratton SM, Brents LK, Moran CL*, Endres GW*, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH*.

Cytochrome p450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos. 2012; 40(11):2174-2184.

Seely KA*, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL.

AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies. Neuropharmacol. 2012; 63(5):905–915.

Brents LK, Medina-Bolivar F, Seely KA*, Nair V, Bratton SM, Ñopo-Olazabal L, Patel RY, Liu H, Doerksen RJ, Prather PL, Radominska-Pandya A.

Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors. Xenobiotica. 2012; 42(2):139–156.

Horvath TD, Stratton SL, Bogusiewicz A, Owen SN, Mock DM, Moran JH*.

Quantitative measurement of urinary excretion of 3-hydroxyisovaleryl carnitine by LC-MS/MS as an indicator of biotin status in humans. Anal Chem. 2010; 82(22):9543-9548.

Shevyrin V,  Melkozerov, V, Endres GW, Shafran Y, Morzherin Y.  

On a New Cannabinoid Classification System: A Sight on the Illegal Market of Novel Psychoactive Substances. Cannabis and Cannabinoid Research Volume 1.1, 2016

Moran JH*.

Smart resource allocation needed to study “legal highs”. Nat Med. 2011; 17(11):1339.

Chimalakonda KC, Bratton SM, Le VH, Yiew KH, Dineva A, Moran CL*, James LP, Moran JH*, Radominska-Pandya A.

Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metab Dispos. 2011; 39(10):1967-1976.

Chimalakonda KC, Moran CL*, Kennedy PD, Endres GW*, Uzieblo A, Dobrowolski PJ, Fifer EK, Lapoint J, Nelson LS, Hoffman RS, James LP, Radominska-Pandya A, Moran JH*.

Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine. Anal Chem. 2011; 83(16):6381-6388.

Lapoint J, James LP, Moran CL*, Nelson LS, Hoffman RS, Moran JH*. (2011)

Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila). 49(8), 760-764.

Brents LK, Reichard EE, Zimmerman SM, Moran JH*, Fantegrossi WE, Prather PL.

Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One. 2011;6(7):e21917.

Moran CL*, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW*, Ciske FL, Kramer JB, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, Prather PL, James, LP, Radominska-Pandya A, Moran JH*.

Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem. 2011; 83(11):4228-4236.

Mock DM, Stratton SL, Horvath TD, Bogusiewicz A, Matthews NI, Henrich CL, Dawson AM, Spencer HJ, Owen SN, Boysen G, Moran JH*.

Urinary excretion of 3-hydroxyisovaleric acid and 3-hydroxyisovaleryl carnitine increases in response to a leucine challenge in marginally biotin-deficient humans. J Nutr. 2011; 141(11):1925-1930.

Brents LK, Reichard EE, Zimmerman SM, Moran JH*, Fantegrossi WE, Prather PL.

Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One. 2011; 6(7):e21917.

Stratton SL, Horvath TD, Bogusiewicz A, Matthews NI, Henrich CL, Spencer HJ, Moran JH*, Mock DM.

Urinary excretion of 3-hydroxyisovaleryl carnitine is an early and sensitive indicator of marginal biotin deficiency in humans. J Nutr. 2011; 141(3):353-358.

Seely KA*, Prather PL, James LP, Moran JH*.

Marijuana-based drugs: Innovative therapeutics or designer drugs of abuse? Mol Interv. 2011; 11(1):36-51.

Jones DR, Kim SY, Guderyon M, Yun CH, Moran JH*, Miller GP.

Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin. Chem Res Toxicol. 2010; 23(5):939-945.

Stratton SL, Horvath TD, Bogusiewicz A, Matthews NI, Henrich CL, Spencer HJ, Moran JH*, Mock DM.

Plasma concentration of 3-hydroxyisovaleryl carnitine is an early and sensitive indicator of marginal biotin deficiency in humans. Am J Clin Nutr. 2010; 92(6):1399-1405.

PinPoint Test, LLC

Dr. Jeffery H. Moran
AR Children’s Hospital Research Institute
13 Children’s Way, Slot 841
Little Rock, Arkansas 72202
501-891-0070

PinPoint Testing, LLC